z-logo
open-access-imgOpen Access
Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)
Author(s) -
Li Chen,
Hongming Zhu,
Yan Li,
Qi-Fa Liu,
Yu Hu,
Jian-Feng Zhou,
Jie Jin,
Jian-Da Hu,
Ting Liu,
Depei Wu,
Jie-Ping Chen,
Yong-Rong Lai,
Jianxiang Wang,
Juan Li,
Jian-Yong Li,
Xin Du,
Xin Wang,
Ming-Zhen Yang,
Jinsong Yan,
Gui-Fang Ouyang,
Li Liu,
Ming Hou,
XiaoJun Huang,
Xiao-Jing Yan,
Dan Xu,
WeiMing Li,
Deng-Ju Li,
Yinjun Lou,
Zheng-Jun Wu,
Ting Niu,
Ying Wang,
Xiaoyang Li,
Jian-Hua You,
Hui-Jin Zhao,
Yú Chen,
Yang Shen,
Qiu-Sheng Chen,
Jian Li,
Bingshun Wang,
Weili Zhao,
JianQing Mi,
Kankan Wang,
Jiong Hu,
Zhu Chen,
SaiJuan Chen,
Jun-Min Li
Publication year - 2021
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2020382118
Subject(s) - arsenic trioxide , medicine , acute promyelocytic leukemia , regimen , clinical trial , chemotherapy , randomized controlled trial , oncology , adverse effect , chemotherapy regimen , intensive care medicine , retinoic acid , arsenic , biochemistry , materials science , chemistry , metallurgy , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom